The Alzheimer's Accountability and Investment Act (Public Law 118-93), enacted on October 1, 2024, mandates that the National ...
The finding has implications for all of us, write Harvard physician-researchers Christopher Worsham and Anupam Jena.
A Potential Game-Changer for Mental Health TreatmentsSetting New Benchmarks: 65% Response Rate Shown in Completed Depression ...
Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease ...
Biogen (BIIB) and Eisai's (ESALF) (ESAIY) announce that U.S. FDA agreed to review their subcutaneous form of Alzheimer's ...
New expensive but disease-modifying treatments are expected to foster Alzheimer’s disease market growth globally, according ...